Company: TELO
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010298
Chunk: 13

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 8
Chunk 13
---
 achieving capital raise milestones. Each component under the 2025 Program may be achieved
and a corresponding payout made independent of the other components, but only after such component meets the minimum threshold of $50,000
 before any bonus payments will be made.

Under
the EICP, Mr. Aminov will be eligible until 2032 for certain long-term incentives based upon the
Company reaching certain market capitalization values, raising capital, and the progress of the Company’s drug candidates. Any
awards or grants received by Mr. Aminov under the EICP is subject to prior board approval. As the awards have not been granted officially
through board approval, there is no grant date under ASC 718, and therefore no measurement date for the value of such awards

Mr.
Aminov will also be entitled to an amount equal to 3% of the total value of any mergers and acquisition or strategic transactions completed
by the Company.

The
Board and the Committee, each in its sole discretion, generally retain the right to amend, supplement, supersede or cancel any awards
under the EICP for any reason, and reserve the right to determine whether and when to pay out any bonus amounts pursuant to or outside
of the EICP, regardless of the achievement of the performance targets.

13

Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The
following discussion and analysis should be read in conjunction with the Condensed Financial Statements and Notes thereto included elsewhere
in this Quarterly Report. This discussion contains certain forward-looking statements that involve risks and uncertainties. The Company’s
actual results and the timing of certain events could differ materially from those discussed in these forward-looking statements as a
result of certain factors, including, but not limited to, those set forth herein and elsewhere in this Quarterly Report and in the Company’s
other filings with the SEC. See “Cautionary Note Regarding Forward Looking Statements” below.

As
used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, unless otherwise indicated,
the terms “the Company”, “we”, “us”, “our” and similar terminology refer to Telomir Pharmaceuticals,
Inc.

Background
of the Company

Telomir-1
is a novel oral small molecule designed to regulate essential metal ions—such as iron, copper, and zinc—that are associated
with oxidative stress, telomere shortening, and cellular aging. By modulating these ions, Telomir